Tactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system. The device retains its indications for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, in pediatric through geriatric patients.
Enhancements include a lighter, more adjustable vest, an intuitive controller, and built-in Wi‑Fi and Bluetooth for connected care. These features are designed to improve comfort, simplify setup and operation, and provide real-world therapy data to patients, clinicians, and DME providers to support adherence and reimbursement.
Loading...
Loading translation...
Positive
Full commercial launch of next-generation AffloVest HFCWO therapy system
Maintains indications across pediatric to geriatric chronic respiratory populations
Lighter, more adjustable vest designed to fit a broad range of body types
Built-in Wi-Fi and Bluetooth enable connected care and therapy tracking
Real-world utilization data supports clinicians and DME providers with reimbursement requirements
Negative
None.
News Market Reaction – TCMD
+1.79%
+1.79%Session close to close
In the Jun 2 session, TCMD gained 1.79%, reflecting a mild positive market reaction.
This announcement details the full commercial launch of TCMD’s next‑generation AffloVest HFCWO syste...
Analysis
This announcement details the full commercial launch of TCMD’s next‑generation AffloVest HFCWO system, emphasizing reduced weight, improved adjustability, and built‑in connectivity for chronic respiratory patients. It follows earlier FDA 510(k) clearance and recent strong revenue growth. The news highlights a shift toward connected at‑home therapies and real‑world data for clinicians and DME partners. Investors may watch future disclosures on adoption, reimbursement support, and how this platform contributes to guidance of $360M–$368M in 2026 revenue.
Strong Q4 and full-year revenue with higher adjusted EBITDA and guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent fundamental and corporate updates, especially earnings, have generally coincided with positive single- to high-teens percentage moves.
Recent Company History
Over the last few months, TCMD has reported strong growth, with Q4 2025 revenue of $103.6M and full-year 2025 revenue of $329.5M, followed by Q1 2026 revenue of $75.3M and updated 2026 guidance to $360M–$368M. These earnings events saw price reactions of 17.83% and 7.22%, respectively. The company also strengthened its board and received FDA 510(k) clearance for a next‑generation AffloVest device, setting the stage for today’s full commercial launch announcement.
Key Terms
high-frequency chest wall oscillation, hfcwo, cystic fibrosis, bronchiectasis, +4 more
A wearable medical therapy that uses a vibrating vest to gently squeeze the chest and loosen mucus in the lungs, helping patients breathe more easily and reduce infections. Investors watch it because demand, clinical evidence, insurance coverage and regulatory decisions determine sales and recurring revenue for companies making or selling these devices, much like how the success of a popular tool depends on usefulness, safety and who will pay for it.
hfcwomedical
"HFCWO therapy, including AffloVest, mechanically mobilizes and facilitates removal"
High-frequency chest wall oscillation (HFCWO) is a noninvasive respiratory therapy delivered by a wearable vest or device that gently vibrates the chest to loosen and move mucus from the lungs, like a mechanical hand shaking loose sticky debris. It matters to investors because HFCWO devices address chronic respiratory conditions, can drive recurring product and service revenues, and are sensitive to clinical evidence, reimbursement rules and device adoption trends that affect market growth.
cystic fibrosismedical
"including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations"
A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.
bronchiectasismedical
"including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations"
Bronchiectasis is a long-term lung condition where airway walls become damaged and widened, causing mucus to build up like clogged pipes; this leads to repeated infections, coughing, breathlessness and progressive loss of lung function. Investors care because the condition drives demand for drugs, inhaled therapies, diagnostics and hospital care, shapes clinical trial design and regulatory risk, and creates predictable markets for companies developing treatments or care solutions.
airway clearancemedical
"Effective management of chronic respiratory conditions requires a multimodal approach in which airway clearance plays a critical"
Airway clearance is a set of treatments and devices that help remove mucus and other secretions from the lungs and breathing passages so air can flow more freely. For investors, it matters because effective airway clearance reduces hospital visits, improves quality of life, and drives demand for medical devices, drugs and services—think of it like clearing clogged pipes to restore proper flow in a building’s plumbing.
pharmacological agentsmedical
"alongside other therapies, including pharmacological agents. While these medications target inflammation"
Pharmacological agents are chemical or biological substances designed to change how the body or a disease behaves, such as medicines, vaccines, or experimental compounds. Think of them as specialized tools intended to fix or influence a biological problem; their success, safety and regulatory approval directly affect a healthcare company's future sales, costs and risk profile, so investors watch clinical progress, approvals and patent status closely.
durable medical equipmenttechnical
"clinicians, and durable medical equipment (DME) partners, the next-generation AffloVest"
Durable medical equipment (DME) includes long-lasting devices used to help people manage health conditions and improve mobility, such as wheelchairs, hospital beds, and oxygen machines. These items are designed to be reused and are often covered by health insurance. For investors, DME represents a steady market because demand remains consistent as populations age and healthcare needs grow.
wifitechnical
"next-generation AffloVest® Airway Clearance Therapy" ... built-in Wi-Fi and Bluetooth connectivity"
Wi-Fi is a technology that lets devices like phones, laptops, and sensors connect wirelessly to the internet and to each other over short distances, using radio signals instead of cables. For investors it matters because Wi‑Fi affects how products work, how businesses run and scale, and where revenue or costs may come from—think of it as the invisible roadway that enables digital services, office productivity, retail checkout and many internet‑connected devices to function reliably.
Reduced Weight, Expanded Size Adjustability, and Built-in Wi-Fi & Bluetooth® Deliver a More Comfortable, Connected Patient Experience Without Compromising Clinical Effectiveness
MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence.
“Commercial introduction of the next-generation AffloVest system reflects our ongoing commitment to innovation that improves the lives of patients who depend on our therapies every day, and we are pleased to make our upgraded airway clearance product available ahead of this year’s winter respiratory season,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “Importantly, the new system preserves the same proven clinical foundation that clinicians trust, while delivering a more comfortable and connected experience, reinforcing AffloVest’s position as a versatile solution for chronic respiratory patients, including those with bronchiectasis, at every stage of life. We designed this new system with the entire care network in mind, from the patient managing their condition to the clinician guiding their care.”
Effective management of chronic respiratory conditions requires a multimodal approach in which airway clearance plays a critical, complementary role alongside other therapies, including pharmacological agents. While these medications target inflammation and infection, they do not directly address retained mucus, one of the primary drivers of impaired lung function and disease progression. HFCWO therapy, including AffloVest, mechanically mobilizes and facilitates removal of secretions to improve ventilation and support overall respiratory health, and published clinical literature demonstrates its ability to enhance mucus transport and reduce secretion burden.
Based on feedback from patients, clinicians, and durable medical equipment (DME) partners, the next-generation AffloVest was intentionally designed with a focus on simplifying setup and improving the overall treatment experience. The new system features a lighter and more adjustable vest than its predecessor to accommodate a broad range of patient ages and body types. Paired with a redesigned controller built for intuitive navigation, AffloVest is now easier to put on, simpler to operate, and more comfortable to wear at home and on the go.
The next-generation AffloVest also offers built-in Wi-Fi and Bluetooth connectivity, enabling patients to visualize their treatment progress and stay engaged with therapy, while equipping clinicians with real-world data needed to have more informed, personalized treatment discussions. DME providers also gain access to therapy utilization data that supports patient care and reimbursement requirements with payers.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic inflammatory lung disease by helping them live better and care for themselves. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
What did Tactile Medical (NASDAQ: TCMD) announce about the AffloVest airway clearance system on June 2, 2026?
Tactile Medical announced the full commercial launch of its next-generation AffloVest HFCWO therapy system. According to Tactile Medical, the new system enhances comfort, ease of use, and connected care while maintaining indications for chronic neuromuscular and respiratory conditions across pediatric through geriatric patients.
What are the key new features of Tactile Medical’s next-generation AffloVest (TCMD)?
The next-generation AffloVest features a lighter, more adjustable vest and a redesigned, intuitive controller. According to Tactile Medical, it also adds built-in Wi-Fi and Bluetooth, allowing patients, clinicians, and DME providers to access therapy utilization data and support more personalized, connected airway clearance care.
For which conditions and patient groups is the new AffloVest from Tactile Medical (TCMD) indicated?
The new AffloVest system is indicated for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis. According to Tactile Medical, it is designed for use across pediatric and geriatric populations, accommodating a broad range of ages and body types with its more adjustable vest design.
How does AffloVest HFCWO therapy from Tactile Medical (TCMD) support airway clearance?
AffloVest delivers high-frequency chest wall oscillation to mechanically mobilize and help remove retained mucus. According to Tactile Medical, published clinical literature shows HFCWO can enhance mucus transport and reduce secretion burden, supporting ventilation and overall respiratory health as part of a multimodal treatment approach.
How do the Wi-Fi and Bluetooth features of Tactile Medical’s AffloVest benefit patients and clinicians?
Built-in Wi-Fi and Bluetooth let patients visualize treatment progress and stay engaged with therapy. According to Tactile Medical, clinicians and DME providers can access real-world utilization data, supporting informed treatment discussions, long-term adherence, and meeting reimbursement documentation requirements for airway clearance therapy.
How is the user experience improved in the next-generation AffloVest launched by Tactile Medical (TCMD)?
The user experience is enhanced by a lighter vest, greater size adjustability, and an intuitive controller. According to Tactile Medical, these changes simplify setup, make the device easier to put on and operate, and improve comfort for home and on-the-go airway clearance therapy.
